Shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) were down 2.1% during mid-day trading on Wednesday . The company traded as low as $3.75 and last traded at $3.80, with a volume of 58,676 shares traded. The stock had previously closed at $3.88.

The stock has a 50 day moving average price of $3.98 and a 200 day moving average price of $3.99. The firm’s market cap is $124.24 million.

An institutional investor recently bought a new position in VBI Vaccines, Inc. – stock. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of VBI Vaccines, Inc. – (NASDAQ:VBIV) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,433,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,497,000. Cambridge Investment Research Advisors Inc. owned 6.09% of VBI Vaccines, Inc. – as of its most recent filing with the SEC.

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.